Abstract
We compared two doses of recombinant human granulocyte-stimulating factor (G-CSF) for stem cell mobilisation in 90 healthy donors for allogeneic stem cell transplantation in a retrospective analysis. Group I (n = 46) received 10 μg/kg G-CSF (filgrastim) given as 5 μg/kg twice daily, and group II (n = 44) received 16 μg/kg, given as 8 μg/kg twice daily with a 12-h interval. The groups were well-balanced for age and body-weight. G-CSF application was performed on an out-patient basis, and leukapheresis was started in all donors on day 5. The most frequent side-effects of G-CSF were grade I/II, bone pain, headache and fatigue in both groups, whereas grade III of bone pain, headache and fatigue occurred in the 2 × 8 μg/kg group only. One serious non-fatal event with non-traumatic spleen rupture occurred in the 2 × 5 μg/kg group. The CD34+cell count in the first apheresis of all donors was 5.1 × 106/kg donor weight (range, 1.5–19.3). The CD34+ cell harvest was higher in the 2 × 8 μg/kg group than in the 2 × 5 μg/kg group (7.1 × 106/kg vs 4.9 × 106/kg; P = 0.09). The target of collecting >5.0 × 106 CD34+ cells/kg donor weight with one apheresis procedure was achieved in 45% of group I and in 61% of group II, respectively. Administering G-CSF at a dosage of 8 μg/kg twice daily leads to a higher CD34+ cell yield than a dosage of 2 × 5 μg/kg, but is associated with increased toxicity and higher cost.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilised by recombinant human granulocyte colony-stimulating factor Blood 1995 85: 1655 1658
Körbling M, Przepiorka D, Huh YO et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts Blood 1995 86: 2842 2848
Schmitz N, Bacigalupo A, Hasenclever D et al. Allogeneic bone marrow transplantation vs filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: first results of a randomised multicentre trial of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 1998 21: 995 1003
Brown RA, Adkins D, DiPersio J et al. Allogeneic peripheral blood stem cell transplantation is associated with an increased risk of chronic graft-versus-host disease Blood 1997 90: 225a
Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim for mobilisation and collection of peripheral blood progenitor cells in normal volunteers Blood 1995 86: 4437 4445
Anderlini P, Przepiorka D, Seong D et al. Clinical toxicity and laboratory effects of filgrastim mobilisation and blood stem cell apheresis from normal donors and analysis of charges for the procedures Transfusion 1996 36: 590 595
Tanaka R, Matsudaira T, Tanaka I et al. Kinetics and characteristics of peripheral blood progenitor cells mobilised by G-CSF in normal healthy volunteers Blood 1994 84: 541a
Dreger P, Haferlach T, Eckstein V et al. G-CSF mobilised peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilisation, and composition of the graft Br J Haematol 1994 87: 609 613
Mavroudis D, Read E, Cotter-Fox M et al. CD34+ cell dose predicts survival, posttransplant morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic malignancies Blood 1997 89: 4226 4235
Sierra J, Storer B, Hansen JA et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: effect of leukemic burden, donor HLA-matching, and marrow cell dose Blood 1997 89: 4226 4235
Engelhardt M, Bertz H, Afting M et al. High- vs standard-dose filgrastim (rhG-CSF) for mobilisation of peripheral blood progenitor cells from allogeneic donors and CD34+ immunoselection J Clin Oncol 1999 17: 2160 2172
Weaver CH, Birch R, Greco FA et al. Mobilisation and harvesting of peripheral blood stem cells: randomised evaluations of different doses of filgrastim Br J Haematol 1998 100: 338 347
Zeller W, Gutensohn K, Stockschläder M et al. Increase of mobilised CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis Bone Marrow Transplant 1996 17: 709 713
Höglund M, Smedmyr B, Simonsson B . Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF Bone Marrow Transplant 1996 18: 279 283
Kröger N, Renges H, Krüger W et al. A randomised comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilisation in healthy donors for allogeneic transplantation Br J Haematol 2000 111: 761 765
Sutherland DR, Anderson L, Keeney M . The ISHAGE guidelines for CD34+ cell determination by flow cytometry J Hematother 1996 5: 213
Stroncek DF, Clay ME, Petzholdt ML . Treatment of normal individuals with granulocyte stimulating-factor: donor experiences and the effect on peripheral CD34+ cell counts and on the collection of peripheral blood stem cells Transfusion 1996 36: 601 610
Martinez C, Urbano-Ispizua A, Marin P et al. Efficacy and toxicity of a high-dose G-CSF schedule for peripheral blood progenitor cell mobilisation in healthy donors Bone Marrow Transplant 1999 24: 1273 1278
Majolini I, Scime R, Vasta S et al. Mobilisation and collection of PBSC in healthy donors: comparison between two schemes of rhG-GSF administration Eur J Hematol 1996 57: 214 221
Pönisch W, Leiblein S, Edel E et al. rhG-CSF mobilisation and collection of peripheral blood progenitor cells in 91 normal donors: comparison between once a day versus twice a day G-CSF administration Bone Marrow Transplant 2000 25: (Suppl.) 870
Arbona C, Prosper F, Benet I et al. Comparison between once a day vs twice a day G-CSF for mobilisation of peripheral blood progenitor cells in normal donors for allogeneic PBSC transplantation Bone Marrow Transplant 1998 22: 39 45
de Haas M, Kerst JM, van der Schoot C et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effect on circulating neutrophils Blood 1994 84: 3885 3889
Somlo G, Sniecinski I, Odom-Maryon T et al. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony-stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer Blood 1997 89: 152 158
Kröger N, Zeller W, Hassan HT et al. Schedule dependency of granulocyte colony stimulating factor in peripheral blood progenitor cell mobilisation in breast cancer patients Blood 1998 91: 1828
Becker PS, Wagle M, Matous S . Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor: occurrence in an allogeneic donor of peripheral blood stem cells Biol Blood Marrow 1997 3: 45 49
Anderlini P, Przepiorka D, Huh Y et al. Duration of filgrastim mobilisation and apheresis yield of CD34+ progenitor cells and lymphoid subsets in normal donors for allogeneic transplantation Br J Haematol 1996 93: 940 942
Kröger N, Krüger W, Renges H et al. Comparison of progenitor cell collection on day 4 or day 5 after steady-state stimulation with G-CSF alone in breast cancer patients: Influence on CD34+ cell yield, subpopulation and tumorcell contamination J Hematother Stem Cell Res 2000 9: 111 117
Kobbe G, Soehngen D, Heyll A . Large volume leukapheresis maximizes the progenitor cell yield for allogeneic peripheral blood progenitor donation J Hematother 1997 6: 125 131
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kröger, N., Renges, H., Sonnenberg, S. et al. Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors. Bone Marrow Transplant 29, 727–730 (2002). https://doi.org/10.1038/sj.bmt.1703509
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1703509
Keywords
This article is cited by
-
Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF?
Bone Marrow Transplantation (2007)
-
An analysis of the optimal timing of peripheral blood stem cell harvesting following priming with cyclophosphamide and G-CSF
Bone Marrow Transplantation (2007)
-
Clinical applications of granulocyte colony-stimulating factor: an update and summary
Annals of Hematology (2003)